

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Gaush Meditech Ltd**

**高視医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2407)**

## **CHANGE IN CHIEF EXECUTIVE OFFICER**

The Board hereby announces that, with effect from March 25, 2024:

1. Mr. Liu Xinwei has been appointed as the new Chief Executive Officer and ceased to act as the co-chief executive officer of the Company; and
2. Mr. Gao Tieta has ceased to act as the Chief Executive Officer but will remain as an executive Director and the chairman of the Board.

## **CHANGE IN CHIEF EXECUTIVE OFFICER**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, with effect from March 25, 2024, Mr. Liu Xinwei (劉新偉) (“**Mr. Liu**”), currently an executive Director and the co-chief executive officer of the Company, has been appointed as the new chief executive officer (the “**Chief Executive Officer**”) of the Company. In light of Mr. Liu’s new role as the Chief Executive Officer, Mr. Liu has ceased to act as the co-chief executive officer of the Company with effect from the same date. As an executive Director and the Chief Executive Officer, Mr. Liu is responsible for the overall operations and management of the Group, participating in the formulation of business plans and annual targets and leading the achievement of the Group’s annual targets.

With effect from the same date, Mr. Gao Tieta (高鐵塔) (“**Mr. Gao**”), an executive Director and the chairman of the Board, has ceased to act as the Chief Executive Officer due to a redesignation of duties in the Group. Upon the cessation as the Chief Executive Officer, Mr. Gao will remain as an executive Director and the chairman of the Board, and he will be responsible for the overall strategic development of the Group, overseeing the overall operations and management of the Group and participating in the decision-making of major issues such as formulation of investment plans and annual business targets.

Mr. Gao is entitled to receive a fixed salary of RMB860,000 per annum, plus a discretionary management bonus, as determined by the Board after considering the recommendation of the remuneration committee of the Company with reference to his duties and responsibilities with the Company and prevailing market conditions.

Mr. Gao has confirmed that he has no disagreement with the Board and he is not aware of any matters in connection with his cessation as the Chief Executive Officer that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The biographical details of Mr. Liu are set out as follows:

Mr. Liu, aged 42, has around 11 years of experience in the medical industry. Mr. Liu joined the Group as the board secretary of Gaush Medical Corporation\* (高視醫療科技集團有限公司), a wholly-owned subsidiary of the Company, in May 2016. Mr. Liu served as the chief financial officer of the Company from December 2018 to January 2023. He has served as a Director since November 21, 2019 and was re-designated as the executive Director on November 18, 2021. Mr. Liu served as the co-chief executive officer of the Company from January 2023 to March 2024. Mr. Liu also holds directorship in Gaush Europe GmbH, Gaush Coöperatief U.A., Gaush Teleon Ltd\* (高視泰靚醫療科技有限公司) and Gaush Neotech Ltd\* (高視創新科技有限公司), all of which are wholly-owned subsidiaries of the Company.

Mr. Liu received his master degree in business administration from Tsinghua University (清華大學) in July 2013. He received his bachelor degree in information engineering from Zhejiang University (浙江大學) in June 2004. Mr. Liu holds a legal professional qualification (法律職業資格) certificate issued by the Ministry of Justice of the PRC in March 2013 and became a non-practising member of the Beijing Institute of Certified Public Accountants (北京註冊會計師協會) in April 2017.

Mr. Liu has entered into a service contract (the “**Service Contract**”) with the Company for his directorship and role as a senior management of the Company. The Service Contract may be renewed in accordance with the amended and restated memorandum and articles of association of the Company and the applicable laws, rules and regulations. No separate service contract will be entered into between the Company and Mr. Liu in respect of his appointment as the Chief Executive Officer and the terms of the existing Service Contract remain unchanged. Pursuant to the Service Contract, the initial term of his appointment as an executive Director is three years commencing from December 12, 2022 or until the third annual general meeting of the Company since the date of his appointment as an executive Director, whichever is sooner, unless terminated by not less than one month’s prior notice in writing served by either party to the other and subject to retirement by rotation and re-election in accordance with the amended and restated memorandum and articles of association of the Company, and there is no specified term for his appointment as the Chief

Executive Officer. Mr. Liu is entitled to receive a fixed salary of RMB820,000 per annum, plus a discretionary management bonus, as determined by the Board after considering the recommendation of the remuneration committee of the Company with reference to his duties and responsibilities with the Company and prevailing market conditions.

As of the date of this announcement, Mr. Liu is deemed to be interested in 955,879 shares of the Company (the “**Shares**”), representing approximately 0.65% of the total issued Shares.

Saved as disclosed above and as of the date of this announcement, Mr. Liu has confirmed that (i) he did not hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) he did not have any other relationship with any Director, senior management or substantial shareholders or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company; (iii) he was not interested or deemed to be interested in any other Shares, underlying Shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iv) he did not hold other positions within the Group; (v) there is no other information that is required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules; and (vi) there is no other matters that need to be brought to the attention of the shareholders of the Company and the Stock Exchange relating to Mr. Liu’s appointment as the Chief Executive Officer.

By order of the Board  
**Gaush Meditech Ltd**  
**Mr. Gao Tieta**  
*Chairman and Executive Director*

Hong Kong, March 25, 2024

*As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.*

\* *For identification purposes only*